Drug
Bintrafusp alfa clinical trials
Also written M7824 and MSB0011359C.
- studies test it
- 46
- open now
- 2
- in phase 3
- 3
- first study started
- 2015
Keep track of what changes. Save the bintrafusp alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- M7824
- 36
Combined with it in one product
Studies by the year they started
46 studies that test it; most in 2020 (16)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 9 |
| 2019 | 4 |
| 2020 | 16 |
| 2021 | 12 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 22
- Phase 2
- 34
- Phase 3
- 3
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 34
National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (10) · EMD Serono Research & Development Institute, Inc. (10) · Institut Bergonié (1) · Fundación GECP (1) · Merck KGaA, Darmstadt, Germany (1) · The University of Hong Kong (1) · Yonsei University (1)
Often tested with
Tested in the same studies.
Paclitaxel (3) · Carboplatin (3) · Immunocytokine NHS-IL12 (2) · Cisplatin (2) · Gemcitabine (2) · Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 (1) · INCB057643 (1) · Albumin-Bound Paclitaxel (1)
Studies
Open first, then newest update. How each study uses bintrafusp alfa is read from its arms, and is right about nine times in ten.
Testing it · 46
- PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi SarcomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT04303117Written as M7824
- TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapYRecruitingNot applicableAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT04481256Written as Bintrafusp alfa
- Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04417660Written as M7824
- A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT04708470Written as Bintrafusp Alfa
- Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic CholangiocarcinomaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT04708067Written as Bintrafusp Alfa
- HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT04432597Written as M7824
- Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced SarcomaActive, not recruitingPhase 2Institut BergoniéNCT04874311Written as Bintrafusp alfa
- Combination Immunotherapy in Subjects With Advanced HPV Associated MalignanciesCompletedPhase 1/2National Cancer Institute (NCI)NCT04287868Written as M7824
- First in Human Study of M6223CompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT04457778Written as Bintrafusp alfa
- Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04789668Written as Bintrafusp Alfa
- Bintrafusp Alfa Program Rollover StudyCompletedPhase 3EMD Serono Research & Development Institute, Inc.NCT05061823Written as Bintrafusp alfa
- Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural MesotheliomaCompletedPhase 2Fundación GECPNCT05005429Written as Bintrafusp alfa
- Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung CancerTerminatedPhase 2Mayo ClinicNCT04396535Written as Bintrafusp Alfa
- Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).CompletedPhase 2National Cancer Institute (NCI)NCT05012098Written as Bintrafusp alfa/M7824
- Combination Immunotherapy in Biochemically Recurrent Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT03315871Written as MSB0011359C (M7824)
- M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)CompletedPhase 3EMD Serono Research & Development Institute, Inc.NCT03631706Written as M7824
- Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)CompletedPhase 1/2National Cancer Institute (NCI)NCT04574583Written as M7824
- M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite InstabilityCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03436563Written as Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid TumorsCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT02699515Written as MSB0011359C
- Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell CancerTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04220775Written as Bintrafusp Alfa
See all 46 studies that test bintrafusp alfa →
Given in every arm · 10 — bintrafusp alfa is usual care beside what is tested
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT04633252Written as M7824
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04235777Written as M7824
- Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)CompletedPhase 1/2National Cancer Institute (NCI)NCT03493945Written as M7824
- Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus InfectionCompletedPhase 1/2National Cancer Institute (NCI)NCT04247282Written as M7824
- M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT03554473Written as M7824
- Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal CancersCompletedPhase 2National Cancer Institute (NCI)NCT04491955Written as MSB0011359C
- Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)CompletedPhase 1GlaxoSmithKlineNCT02723955Written as Bintrafusp alfa
- Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)CompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT04551950Written as M7824
- Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT04327986Written as M7824
- BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)TerminatedPhase 1National Cancer Institute (NCI)NCT04296942Written as M7824
Codes
What other systems call bintrafusp alfa · ClinicalTrials.gg INT017419
- UNII (FDA) NW9K8C1JN3BINTRAFUSP ALFAOne source FDA
- NCI Thesaurus C124229Bintrafusp AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NW9K8C1JN3 | BINTRAFUSP ALFA | One source FDA |
| NCI Thesaurus | C124229 | Bintrafusp Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.